Comparison of Tranexamic acid, Remifentanil, and Hydralazine on the bleeding volume during Dacryocystorhinostomy surgery.
Blood loss
dacryocystorhinostomy
hemorrhage
induced hypotension
Journal
International journal of physiology, pathophysiology and pharmacology
ISSN: 1944-8171
Titre abrégé: Int J Physiol Pathophysiol Pharmacol
Pays: United States
ID NLM: 101521074
Informations de publication
Date de publication:
2022
2022
Historique:
received:
06
08
2021
accepted:
07
05
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
Bleeding in Dacryocystorhinostomy (DRC) limits the surgeon's sight and access. Tranexamic acid, Remifentanil, and Hydralazine reduce intraoperative blood loss. However, no study has been carried out to compare the efficacy of the latter drugs during DCR surgery. Ninety healthy candidates for DCR surgery with chronic Dacryocystitis (aging 20-80) were randomly assigned in groups of 30 to receive low doses of Tranexamic acid (TXA) (10 mg/kg with a maximum dose of 1000 mg), Remifentanil (0.1 µ/kg), or Hydralazine (0.1 mg/kg). All drugs were infused over 15 minutes before the initiation of surgery. The primary outcome was the bleeding volume during the surgery and until 2 hours in recovery. This study was approved by the Iranian Registry of Clinical Trials with the code of IRCT20210614051574N10 (https://en.irct.ir/trial/62759). Thirty patients (mean age ± SD: 50.48±13.4) were investigated. Mean blood loss volume was lower in Remifentanil and Hydralazine groups compared with the TXA group (P<0.05); there was no significant difference (P>0.05) in bleeding volume between Remifentanil and Hydralazine groups (Tranexamic acid group: 146.83±91 ml, Remifentanil group: 77.6±52.1 ml, Hydralazine group: 80.0±48.7 ml, 95% confidence interval, P<0.05). Our results show that Remifentanil and Hydralazine are more effective than Tranexamic acid in bleeding control.
Sections du résumé
BACKGROUND
BACKGROUND
Bleeding in Dacryocystorhinostomy (DRC) limits the surgeon's sight and access. Tranexamic acid, Remifentanil, and Hydralazine reduce intraoperative blood loss. However, no study has been carried out to compare the efficacy of the latter drugs during DCR surgery.
METHODS
METHODS
Ninety healthy candidates for DCR surgery with chronic Dacryocystitis (aging 20-80) were randomly assigned in groups of 30 to receive low doses of Tranexamic acid (TXA) (10 mg/kg with a maximum dose of 1000 mg), Remifentanil (0.1 µ/kg), or Hydralazine (0.1 mg/kg). All drugs were infused over 15 minutes before the initiation of surgery. The primary outcome was the bleeding volume during the surgery and until 2 hours in recovery. This study was approved by the Iranian Registry of Clinical Trials with the code of IRCT20210614051574N10 (https://en.irct.ir/trial/62759).
RESULTS
RESULTS
Thirty patients (mean age ± SD: 50.48±13.4) were investigated. Mean blood loss volume was lower in Remifentanil and Hydralazine groups compared with the TXA group (P<0.05); there was no significant difference (P>0.05) in bleeding volume between Remifentanil and Hydralazine groups (Tranexamic acid group: 146.83±91 ml, Remifentanil group: 77.6±52.1 ml, Hydralazine group: 80.0±48.7 ml, 95% confidence interval, P<0.05).
CONCLUSION
CONCLUSIONS
Our results show that Remifentanil and Hydralazine are more effective than Tranexamic acid in bleeding control.
Types de publication
Journal Article
Langues
eng
Pagination
177-186Informations de copyright
IJPPP Copyright © 2022.
Déclaration de conflit d'intérêts
None.
Références
Ophthalmol Ther. 2019 Dec;8(4):541-548
pubmed: 31422554
Spine J. 2015 Apr 1;15(4):647-54
pubmed: 25457470
Emerg Med J. 2017 May;34(5):294-301
pubmed: 28249938
Drug Alcohol Depend. 2021 Jan 1;218:108369
pubmed: 33109461
J Vet Med Sci. 2018 Mar 2;80(2):354-360
pubmed: 29269709
Transl Stroke Res. 2020 Oct;11(5):871-881
pubmed: 32056157
Crit Care Clin. 2017 Jan;33(1):85-99
pubmed: 27894501
Ophthalmology. 2017 Feb;124(2):263-267
pubmed: 27986382
Shock. 2021 Nov 1;56(5):782-792
pubmed: 33555842
Eur J Hum Genet. 2015 Nov;23(11):1473-81
pubmed: 25944381
Pregnancy Hypertens. 2020 Jan;19:177-186
pubmed: 32044579
Ophthalmology. 2019 Nov;126(11):1580-1585
pubmed: 31358391
Anaesthesia. 2019 May;74(5):602-608
pubmed: 30663045
Anesth Prog. 2017 Spring;64(1):3-7
pubmed: 28128659
Am J Nephrol. 2020;51(10):764-776
pubmed: 32927458
J Oral Maxillofac Surg. 2018 Sep;76(9):1882.e1-1882.e7
pubmed: 29902418
World Neurosurg. 2019 May;125:e198-e204
pubmed: 30684701
Local Reg Anesth. 2018 Apr 09;11:15-23
pubmed: 29670398
N Engl J Med. 2017 Jan 12;376(2):136-148
pubmed: 27774838
J Oral Maxillofac Surg. 2011 Aug;69(8):2128-34
pubmed: 21497003
J Bone Joint Surg Am. 2018 Sep 5;100(17):1509-1516
pubmed: 30180060
Plast Reconstr Surg. 2018 Feb;141(2):507-515
pubmed: 28938364
Head Neck. 2021 Nov;43(11):E51-E55
pubmed: 34487402
Clin Exp Otorhinolaryngol. 2018 Jun;11(2):81-88
pubmed: 29649861
Int J Oral Maxillofac Surg. 2019 Oct;48(10):1323-1328
pubmed: 30902548
Clin Exp Otorhinolaryngol. 2018 Sep;11(3):151-157
pubmed: 29590744
Br J Anaesth. 2017 Mar 1;118(3):293-295
pubmed: 28203768